CME Group Inc. (NASDAQ: CME) — The Toll Bridge the Market Just Remembered Is Cyclical

An independent fundamental research note Report date: 2026-06-08 Price at analysis: ~$252–257 (June 5–8, 2026) · Shares (Class A): ~359M · Market cap: ~$91B · EV: ~$94B (net cash) Sector: Financials — Financial Exchanges & Data · CIK: 0001156375 · Fiscal year: December

⚡ Claude’s Take

This block is the author’s own subjective opinion and general information only — not investment advice. The analytical body of this article below takes no position, expresses no recommendation, and carries no price target — that discipline is intact everywhere except inside this fenced block.

Verdict: HOLD / great business, full-but-not-crazy price — accumulate on weakness below ~$235, not here. Conviction: medium. Tag: “The toll bridge the market just remembered is cyclical.”

CME is one of the highest-quality business models in all of finance — a regulated, vertically-integrated futures-and-clearing near-monopoly with ~69% operating margins, ~$4.2B of FCF on $84M of capex, a balance sheet that is net-cash once you strip the custodial clearing float, and a triple-locked moat (open-interest liquidity network effect + owned-clearinghouse silo + cross-asset margin offsets worth ~$80B/day to clients). It just printed its fifth consecutive record-volume year. Yet I am only neutral at this price, and that is the honest call. At ~$252 the stock has already fallen ~17% from its ~$304 50-day average on the Coinbase/Kalshi crypto-perpetuals scare and the FMX (Lutnick/BGC) attack on the Treasury franchise — and that de-rate, in my view, is the market correctly removing the secular-grower premium and re-pricing CME as what it actually is: a magnificent, low-beta, GDP-plus toll bridge whose 2025 earnings sit near a rate-volatility cyclical high. On normalized earnings (stripping the ~$306M one-time OSTTRA gain) the trailing P/E is ~23–24x and EV/EBITDA ~19.7x is the richest in the peer group (ICE 15x, CBOE 16x, NDAQ 18x). That premium is defensible but not cheap; it bakes in both the monopoly and the durability of peak-cycle volumes — two bets in one number.

What the market is pricing roughly correctly: a wide-moat annuity worth a premium multiple. What it may be mispricing in either direction is the cyclicality — the bull ignores that rates ADV and the ~$411M float-income spread both lever to a rate-volatility/short-rate regime that is more likely to soften than re-accelerate; the bear over-weights FMX (whose Treasury open interest is ~0.05–0.1% of CME’s record 36.3M-contract pool) and crypto-perps (a rounding error on a complex that is <1.5% of CME volume). The framing is quality-compounder-at-a-fair-price, with a cyclical-peak overhang — not a falling knife, not a bargain. I’d want the ~4.3% all-in cash yield to widen and the multiple to compress toward ~18x normalized earnings (roughly sub-$235, call it a $200–235 accumulation zone) before the risk/reward clearly favors the buyer. The single fact that flips me bullish: evidence that ADV and RPC hold flat-to-up through a demonstrably low-volatility regime (proving the volumes are structural, not cyclical). The single fact that flips me bearish: sustained, growing competitor open interest in the SOFR/Treasury benchmark complex — the one thing that would prove the crown-jewel moat is finally contestable.

1. Executive Summary

CME Group is the world’s largest futures and options-on-futures exchange and derivatives clearinghouse — a vertically integrated trade-execution-plus-clearing utility operating four designated contract markets (CME, CBOT, NYMEX, COMEX) on the Globex platform, with its own clearing house novating every trade. It is, by almost any structural measure, an exceptional business: FY2025 revenue of $6,520.6M (+6%), GAAP operating margin of 64.9% (adjusted 69.4%), net income of $4,072.2M, operating cash flow of $4,277.1M against capex of just $83.5M, and a near-monopoly position in U.S. listed interest-rate, equity-index, and benchmark commodity futures.

The moat is real and measurable. It rests on three reinforcing locks: (1) the open-interest/liquidity network effect (the deepest book wins all incremental flow, and liquidity cannot be replicated from zero); (2) the vertically-integrated, owned clearinghouse — unlike U.S. equity options, U.S. futures are not fungible across venues, so a position opened at CME can only be closed at CME; and (3) cross-asset margin offsets worth ~$80B/day to clients across six asset classes, a switching cost no competitor can match. The moat shows up financially as pricing power without volume loss: blended rate-per-contract (RPC) of $0.696 held roughly flat-to-up across three years even through fee increases, while ADV set a fifth consecutive record. If the moat broke, RPC would compress toward marginal cost — exactly the fate of CBOE’s fungible multi-listed options.

The case for caution is equally evidence-based and threefold. First, cyclicality: 2025 was the fifth straight record-volume year, powered by elevated rate volatility, heavy Treasury issuance, and commodity dislocation — a return to a low-volatility regime is the single largest normalization risk, and it hits the largest complex (rates, ~50% of volume). Second, quiet RPC erosion: blended RPC fell to $0.652 in Q1 2026 (−5% YoY) as growth concentrates in lower-fee micro/retail contracts (+59% in Q4’25) — revenue is growing slower than contracts. Third, a full multiple against an increasingly-contested perimeter: CME carries the highest EV/EBITDA in its peer group (~19.7x), and a normalized P/E near 23–24x, even as FMX (the Lutnick/BGC Treasury-futures venture) and CFTC-blessed crypto perpetuals (Coinbase/Kalshi) attack the two franchises the growth story leans on.

Capital allocation is a genuine strength: a disciplined near-100%-of-FCF payout via a rising regular dividend plus a transparent annual variable special dividend (FY25 $6.15/share, ~$2.2B) that flexes with cash earnings, complemented by a one-time OSTTRA-funded buyback. Incentives are tied to cash earnings and net-income margin (not raw volume), with above-average governance hygiene, though a dual-class structure and the absence of an explicit ROIC/EPS gate are overhangs.

This memo expresses no recommendation and no price target. It concludes that CME is a structurally superb, wide-moat franchise trading at a full price that has already shed its secular-growth premium — leaving a debate that is now less “is it overvalued?” and more “has the market over-corrected a monopoly toward utility pricing, or correctly begun re-rating a peak-cycle, increasingly-contested franchise?”

2. Business Overview

What CME does. CME Group operates the largest regulated marketplace for trading futures and options on futures, and clears those trades through its own derivatives clearing organization. The vertical integration is the defining feature: CME both matches trades (on the Globex central-limit-order-book) and clears them (becoming the buyer to every seller and seller to every buyer via novation), collecting a fee at both ends and controlling the margin/collateral pool. It owns four designated contract markets — Chicago Mercantile Exchange (CME), Chicago Board of Trade (CBOT), New York Mercantile Exchange (NYMEX), and Commodity Exchange (COMEX) — assembled through the transformative CBOT (2007) and NYMEX/COMEX (2008) acquisitions.

The six asset classes. CME’s product breadth across six (now effectively seven, with crypto) asset classes is itself a competitive asset, because it is what enables the cross-asset margin offsets. FY2025 average daily volume (ADV) and growth:

Crypto (Bitcoin, Ether, Solana, XRP) is a seventh, still-small complex — Q4’25 ADV of 379k contracts (+92% YoY), ~$13B notional/day — but strategically important as the beachhead of the retail/24-7 expansion. (FACT: FY2025 10-K MD&A volume tables; Q4-2025 earnings call.)

Interest rates are the ballast and the swing factor. At ~50% of total volume, the rate complex — SOFR and U.S. Treasury futures — is both CME’s anchor franchise and its largest cyclical exposure. SOFR (the LIBOR/Eurodollar successor) and Treasury futures volumes lever to Fed-policy uncertainty, rate volatility, and the relentless growth of U.S. government debt issuance, which structurally expands the universe of risk that must be hedged. (INTERPRETATION.)

Revenue mix (FY2025, $6,520.6M total): (FACT: 10-K MD&A.)

• Clearing & transaction fees: $5,281.1M (81.0%) — transaction-driven; scales with volume × RPC.
• Market data & information services: $803.1M (12.3%, +13%) — the recurring, subscription layer; surpassed $800M for the first time; 31 consecutive quarters of growth; a +3.5% rack-rate increase took effect Jan 1, 2026.
• Other: $436.4M (6.7%) — co-location/connectivity, access fees, the S&P/DJI licensing-agent fee, and collateral management.

Recurring vs. transaction-driven. ~81% of revenue recurs only insofar as volumes do; ~12% (market data) is genuinely subscription-recurring. This is less recurring than peers with large data/analytics segments (e.g., CBOE’s ~26% Data Vantage layer, ICE’s data and mortgage-tech mix), but CME’s transaction base is far more diversified across six asset classes and far less single-product-dependent, which lowers aggregate cyclicality relative to a single-franchise exchange. (INTERPRETATION; cross-read CBOE_2026-06-07 report.)

Index-license dependency. Equity-index futures require third-party index licenses — a structural dependency that is also a barrier protecting CME: an exclusive S&P 500 license (tied to CME’s ~27% ownership of S&P Dow Jones Indices, effectively very long-dated), Nasdaq-100 exclusive through 2039, FTSE Russell exclusive through 2037, and auto-renewing Dow Jones. CME pays a revenue share (the ~$371M “licensing and other fee agreements” line — see ). No single index is as load-bearing for CME as SPX/VIX is for CBOE. (FACT: 10-K Item 1.)

Securities-clearing optionality. CME Securities Clearing Inc. received SEC approval (Dec 2025) to clear U.S. Treasury cash (mandate effective 12/31/2026) and repo (6/30/2027), launching later in 2026. This is both a new adjacent revenue pool and a defensive moat-reinforcer ahead of the mandatory-clearing regime. (FACT: 10-K; Q4-2025 call.)

3. Industry Dynamics

Structure: a vertically-integrated, near-monopoly-at-the-product-level oligopoly. The global listed-derivatives industry is a handful of integrated operators — CME, ICE, Deutsche Börse/Eurex, LSEG/LCH, HKEX, Cboe — each dominant in its own product silo. The decisive structural feature distinguishing futures from options is fungibility. In U.S. listed options, the Options Clearing Corporation is the single shared clearer, so a multi-listed option is fungible across ~18–20 venues and price-competes toward the rebate (this is why CBOE’s multi-listed options earn ~$0.066/contract vs. ~$0.92 for its single-listed proprietary SPX/VIX — a ~14× gap). In U.S. futures, CME runs a vertical silo — it clears its own trades with no fungible competing clearer. A contract opened at CME can only be closed at CME. This is the bedrock of the moat and the single most important fact about the industry. (FACT/INTERPRETATION: 10-K “Competition”; cross-read CBOE report.)

Why it is a natural near-monopoly. Three reinforcing mechanisms:

1. Open-interest pool + liquidity-begets-liquidity. Liquidity concentrates in one venue because every additional participant deepens the book; tighter spreads attract more flow. A rival starting from zero offers worse execution, so flow won’t move — a chicken-and-egg lock.
2. The clearinghouse fungibility/margin-offset lock. Open positions are margined at CME; portfolio/cross-margining only works within CME’s pool. You cannot net a CME long against a rival’s short. Open interest physically cannot migrate without participants simultaneously closing at CME and reopening elsewhere — a coordinated move no single actor will initiate.
3. Cross-asset margin offsets. CME’s six-asset breadth lets clients net risk across rates/equity/energy/metals/FX in one clearinghouse — average daily margin savings of ~$80B (Q4’25, up ~$20B YoY); ~$25B/day within the interest-rate complex alone (including ~$1.5B/day from the FICC/DTCC cross-margining program, up from ~$1B). No competitor offers comparable breadth. (FACT: Q4-2025 call; 10-K financial-safeguards note shows the FY-average figure ~$72B/day.)

Profit pools and the capital cycle (Marathon lens). Industry economics are extraordinary — CME’s incremental margin on an added contract is near 100% (matching/clearing a marginal trade costs almost nothing). Per Capital Returns theory, such returns should attract capital and mean-revert. The capital cycle is operating, but asymmetrically. Supply is flooding the contestable peripheries — FMX (Treasury/SOFR futures), Coinbase/Kalshi (crypto perpetuals), prediction markets (event contracts), cash-FX/fixed-income venues compressing BrokerTec/EBS. But the core open-interest pools are insulated — the silo-clearing + liquidity lock suspends the supply response in the established benchmark franchises (Treasuries, SOFR, E-mini S&P), exactly as an exclusive license suspends it for CBOE’s SPX/VIX. Capital can enter the category but cannot dislodge the incumbent’s pool. This is the central structural judgment of the entire analysis. (INTERPRETATION; frameworks.)

Regulation as a moat input. CFTC primary oversight (plus UK/EU regulators for BrokerTec/EBS/EuroCCP). The regulatory regime is itself part of the moat: it raises the barrier to becoming a designated contract market and registered clearing organization, and the U.S. vertical-silo model (vs. European open-access/interoperable clearing) protects CME’s clearing monopoly. Dodd-Frank central-clearing mandates and Basel III capital rules increase demand for CME’s capital efficiencies — regulation is, on net, a tailwind to the franchise. The mirror-image risk: the silo model is a policy choice, and any U.S. move toward European-style open-access clearing would directly attack lock #2. (FACT/INTERPRETATION: 10-K.)

Verdict — structurally EXCELLENT industry, with a bifurcation. The benchmark-futures + owned-clearing model is one of the best business structures in finance: regulated entry barriers, a self-reinforcing per-product liquidity monopoly, ~100% incremental margins, and regulation that raises demand for the core service. The capital cycle is alive only at the edges; the protected core is large and diversified. The honest caveat is that the perimeter (crypto, event contracts, cash markets, and now a bank-backed rates challenger) is more contested than at any point in a decade.

4. Competitive Position

The moat, named in Greenwald’s taxonomy. CME possesses the strongest available advantage class — economies of scale fused with customer captivity — operating through two reinforcing locks plus an intangible overlay:

• (a) Open-interest / liquidity network effect (demand-side captivity + scale): the deepest book wins all incremental flow; liquidity cannot be replicated by a subscale entrant.
• (b) Clearinghouse margin-offset / capital-efficiency lock (switching cost): the ~$80B/day cross-asset margin savings is a tangible, quantified switching cost — leaving CME means forfeiting offsets across six asset classes.
• © Intangible-asset overlay: the exclusive Nasdaq-100 (to 2039), FTSE Russell (to 2037), and S&P index licenses, plus ownership of SOFR-futures and Treasury-futures benchmark liquidity. (FACT: 10-K; Q4-2025 call.)

Does the moat show up in financials? Yes — the decisive test. A real moat must tie to a financial outcome that would deteriorate without it. CME’s moat manifests as pricing power without volume loss: blended RPC of $0.696 was stable-to-rising (+1% YoY in FY25) even as CME pushed through fee increases (the Q4’25 changes guided to add ~1–1.5% to revenue on similar activity) and a 3.5% market-data rack-rate increase — and ADV still hit a fifth record. A business without a moat cannot raise price and grow volume simultaneously. The counterfactual is explicit: if the open-interest/clearing lock broke, RPC would compress toward the marginal-cost rate of a fungible product (CBOE’s ~$0.066 multi-listed options), and the 69% margin would collapse. That chain — moat → stable RPC → 69% margin — is why the moat is real and not a narrative. (INTERPRETATION; cross-read CBOE report.)

Pressure test: can a competitor replicate the liquidity pool? History says no. CME’s U.S. Treasury open interest hit a record 36.3M contracts (Feb 19, 2026). Multiple well-funded challengers have attacked the rates franchise over two decades (Eurex US, ELX Futures, NYSE Liffe US) and all failed to dislodge open interest — liquidity never moved because no participant will be first to trade into a thin book and forfeit margin offsets. (FACT: CME press release; INTERPRETATION on the historical failures, which the workstream flagged as not independently re-verified from primary sources this session — an Open Question.)

The key threats, assessed skeptically

(a) Coinbase + Kalshi CFTC-regulated crypto perpetual futures (launched June 2026). The CFTC approved Kalshi’s BTCPERP (live June 3, 2026) and Ether perps (June 4); Coinbase plans Solana/XRP/Doge. This is the news behind the early-June 2026 de-rate. Assessment: real in crypto, contained beyond it. CME’s crypto complex is still tiny (379k ADV — a rounding error vs. 28.1M total), so even meaningful crypto share loss is immaterial to group earnings. The genuine threat is second-order: perps are a 24/7, retail-native, capital-efficient format that could become the template attackers use to chip at CME’s retail expansion (micros, event contracts) — and CME’s defensive response (24/7 crypto trading rolling out Q2’26) concedes the format matters. But perps do not touch the institutional rates/equity open-interest pools that drive ~80% of value. Likelihood material to crypto: High; material to group thesis: Low–Medium. (FACT: CFTC PR; INTERPRETATION.)

(b) FMX Futures Exchange (BGC/Lutnick, bank-backed, launched Sept 2024) — the most serious structural attack on the core. FMX directly targets U.S. Treasury & SOFR futures and offers LCH cross-margining (netting Treasury futures against LCH-cleared swaps) — an explicit attempt to neutralize CME’s margin-offset lock with a different offset pool. This is the right strategic attack on the right vulnerability. But traction is negligible against the open-interest moat. FMX SOFR-futures Q2’25 ADV was ~3,200 lots with OI ~21,600 contracts (+82%/+97% QoQ off a near-zero base) — against CME’s 36.3M-contract Treasury OI, FMX’s OI is on the order of ~0.05–0.1%, a ~1,000-to-1,700× gap. FMX’s cash-Treasury platform has real share (~35–40%), but cash-share ≠ futures-share, and the open-interest pool is the moat. The LCH-offset pitch is genuinely clever and the single threat most worth monitoring, because if any challenger ever assembles a credibly large alternative cross-margin pool, the captivity lock weakens. Likelihood of material core-share loss in 24 months: Low; impact-if-realized: Very High — the asymmetry that makes it the #1 watch-item. (FACT: FMX/Markets Media data; INTERPRETATION.)

© 24/7 venues & prediction markets (Kalshi/Polymarket event contracts). CME launched its own event contracts in Q4’25 (>68M traded in six weeks, via FanDuel/DraftKings distribution) and is rolling out 24/7 crypto — i.e., co-opting the format rather than ceding it. Prediction markets compete for retail attention/wallet, not institutional open interest. Low thesis impact. (FACT: Q4-2025 call.)

(d) ICE, Eurex, and Cboe in adjacent products. Each is dominant in its own silo and has historically failed to cross into CME’s core futures pools. Stable oligopolists, not share-takers in CME’s benchmarks. Low–Medium. (FACT: 10-K “Competition”.)

Verdict — DURABLE advantage, not yet eroding, but the perimeter is more contested than in a decade. The moat is intact and measurable: record Treasury OI (36.3M), stable-to-rising RPC through fee hikes, 69% margins, and ~$80B/day of switching costs no rival can match. The triple lock has defeated every prior challenger and is winning vs. FMX so far. Honest caveats: (1) FMX’s LCH cross-margin attack is the first structurally-correct assault on the captivity mechanism — low-probability/very-high-impact, deserving continuous OI monitoring; (2) the crypto/perps/event-contract format shift is a real change in how the next generation of retail traders engage, forcing reactive investment; (3) the U.S. vertical-silo clearing model is a policy dependency.

5. Growth History and Forward Opportunities

Historical growth — high-quality but volume-led. Revenue compounded from $4.69B (FY21) to $6.52B (FY25), a ~8.6% CAGR, with net income rising from $2.64B to $4.07B. The character of that growth matters: it has been overwhelmingly volume-driven, not price-driven. The FY25 clearing-&-transaction-fee bridge decomposes the +$289.7M YoY growth as +$261.2M from volume and only +$28.5M from rate — i.e., ~90% volume, ~10% price, despite an explicit Feb-2025 fee increase. ADV has set five consecutive annual records (28.1M in FY25), with growth broad-based across all six asset classes and a record international business (8.4M ADV, ~30% of volume, +8%). (FACT: 10-K MD&A.)

Organic vs. acquired. Recent growth is almost entirely organic — the last major acquisition was NEX (2018). The growth engine is rising open interest, new client acquisition, new product launches (micros, event contracts, crypto, one-ounce gold, 100-oz silver), and the secular expansion of hedgeable risk (Treasury issuance, commodity volatility, FX). New clients added over the last five years have generated ~$1B of cumulative revenue (~5% of transaction/clearing revenue). (FACT: transcripts; 10-K.)

Forward opportunities — the decoupling thesis. Management is explicitly building growth vectors that decouple from the rate cycle:

• Retail/micro: micro products +59% in Q4’25 to a record 4.4M ADV; >90,000 new retail traders in a single quarter (+56% YoY); ~100–130 global broker partners (Robinhood rollout to 24M customers underway). (FACT: transcripts.)
• Event contracts: launched Q4’25 (sports + economic + financial), >68M traded in six weeks, distributed via the FanDuel JV and DraftKings — a previously-untapped retail segment. (FACT: Q4-2025 call.)
• 24/7 crypto trading rolling out Q2’26; crypto ADV +92% YoY; new Cardano/Chainlink/Stellar/Solana/XRP listings.
• U.S. Treasury clearing mandate (CME Securities Clearing): a new TAM as mandatory clearing of cash Treasuries (12/31/2026) and repo (6/30/2027) takes effect — CME is launching ahead of the mandate, and cross-margining Treasury futures against newly-cleared cash/repo would deepen the offset moat.
• Pricing optionality: a move toward continuous (vs. annual) fee reviews; the April-2026 changes add ~1–1.5% revenue on flat activity; market-data price increases recur.

Verdict — high-quality growth, with a quality caveat. The growth is organic, broad-based, capital-light, and increasingly diversified away from the rate cycle — genuinely high quality. The caveat (developed in ) is that the fastest-growing vectors (micros, retail, event contracts) carry the lowest RPC, so contract growth is outrunning revenue growth, and the secular vectors are still small relative to the rate-cycle-sensitive core. Growth is real; whether it is durable through a volume-normalization year is the central open question.

6. Financial Quality

Revenue quality. Decomposition over three years: (FACT: FY25 10-K income statement.)

The RPC story — the most important earnings-quality signal. Blended rate-per-contract: FY23 $0.692 → FY24 $0.692 → FY25 $0.696 → Q1’26 $0.652 (−5% YoY). The Q1’26 bridge is stark: clearing-&-transaction fees grew +$197.7M as +$257.5M of volume was partly offset by −$59.8M of rate. The mechanism is structural and adverse to the pricing-power narrative: record ADV is increasingly concentrated in (a) micro products (which carry a far lower per-contract fee) and (b) higher volume-tier rebates for large traders. The Feb-2025 fee increase lifted blended RPC just 0.4 cents because mix/tiering ate most of it. This is the central quality caveat to the “record revenue” framing: CME is buying part of its volume growth by giving rate back. (FACT/INTERPRETATION: 10-K, Q1’26 10-Q.)

Market data as the annuity. Market-data revenue grew $663.7M → $710.2M → $803.1M (+13% in FY25), driven by price increases and usage, not trading volume — the steadiest, highest-quality stream, recurring and decoupled from ADV. Concentration is modest (~30% from the two largest resellers). At ~12% of revenue and growing double-digits, it is the closest thing CME has to a true annuity. (FACT: 10-K.)

Gross-up assessment — CME is the clean case. Unlike CBOE (Section 31 pass-throughs, options rebates) the reported ~$6.5B is essentially net revenue. Futures are not subject to the SEC Section 31 fee; “other” revenue is genuine (licensing-agent fees, colocation, access), not custodial pass-through. On a net-revenue basis, CME requires no de-grossing — value it on the reported ~$6.5B. The one pass-through to watch (collateral interest) flows through non-operating income, not revenue (see below). (FACT/INTERPRETATION.)

Margins and operating leverage. (FACT, computed from filings.)

GAAP operating margin expanded ~330bp in two years. The ~69.4% “adjusted” figure is the company’s non-GAAP measure (adds back ~$223.4M intangible amortization and certain items); anchor on GAAP 64.9% plus a separate cash-margin view. Operating leverage is genuine and powerful: expenses grew ~4.2%/year while revenue grew 6–10%. Q1’26 is the cleanest demonstration — revenue +14.5% YoY against expenses +6.8%, driving operating income +18.2% and a 69.7% quarterly operating margin. Economics clearly improve with scale. (FACT.)

Expense detail and the index-license royalty. FY25 opex: compensation $907.0M (+7%, ~40% of opex), technology $283.2M (+11%, Google Cloud migration), professional fees $150.5M (+13%, incl. ~$37M one-time OSTTRA + litigation costs to normalize out), intangible amortization $223.4M, D&A $107.5M, licensing & other fee agreements $371.0M (+4%), other $248.5M. The $371M license line is the royalty CME pays index owners (S&P/DJI, Nasdaq through 2039, FTSE Russell through 2037) — a variable, revenue-shared cost that scales with equity-index volume and caps the margin on the fastest-growing volume class; treat it separately from fixed costs (~16% of opex). SBC is strikingly low at $94.8M (~1.5% of revenue) — CME does not dilute through SBC, and shares actually fell. (FACT: 10-K.)

Balance sheet — the custodial gross-up. Total assets are $198.4B (FY25), but this is almost entirely the clearing pass-through: performance-bond and guaranty-fund contributions of $159,656.1M appear identically on BOTH sides of the balance sheet (current asset and current liability) — clearing-member collateral CME holds custodially, not CME capital (aggregate deposits, including non-cash, ~$347.3B at year-end). These must be stripped to see the real balance sheet. The real balance sheet: cash $4,416.9M + marketable securities $125.0M; long-term debt $3,422.3M (five laddered senior notes to 2048; no short-term debt) — i.e., effectively net cash; goodwill $10,514.7M + intangibles $19,786.0M = ~$30.3B (CBOT/NYMEX/NEX). (FACT: 10-K.)

Book equity is mostly air — value on returns, not book. Total shareholders’ equity is $28,728.2M, but goodwill + intangibles (~$30.3B) exceed it, so tangible book equity is negative (~$(1.6)B). Book value and P/B are economically meaningless here — the franchise value sits in the CFTC-authorized, indefinite-lived trading-product intangibles ($17.2B, never amortized) and goodwill, i.e., the irreproducible exchange license. ROE of ~14.8% understates the true economics because ~$30B of merger goodwill inflates the denominator; on tangible operating capital (property of just $362.7M plus working capital) the business is nearly capital-free and earns several-hundred-percent returns. Use ROIC/return-on-tangible-capital and FCF framing, not ROE/P/B — consistent with standard exchange-valuation discipline. (FACT/INTERPRETATION.)

The float — a rate-sensitive earnings stream. CME earns interest on reinvested cash collateral; FY25 gross earnings were $5,253.6M but $4,842.5M was distributed back to clearing firms, leaving a net retained spread of ~$411M (FY24: ~$274M). This sits in non-operating income, is rate-sensitive, and will compress if the Fed cuts — a quality flag and a swing factor. (FACT: 10-K.)

Cash flow and earnings quality — high. OCF exceeded net income every year (FY25 OCF $4,277.1M vs. NI $4,072.2M, 1.05x); capex was just $83.5M (~1.3% of revenue); FCF ~$4,194M (~64% FCF margin, ~103% of net income). Critically, the custodial collateral swings sit in financing activities, not operating — so OCF is clean of collateral noise. The one normalization: FY25 NI includes a ~$306M pre-tax one-time gain on the OSTTRA JV sale (~$240M after-tax, ~$0.66/share); normalized NI is ~$3.83B. Equity-method income ($371.7M, principally the durable S&P/DJI 27% stake) loses OSTTRA going forward. (FACT: 10-K.)

Verdict — economics improve markedly with scale; earnings quality is high, with two honest caveats. The model is asset-light, ~64–69% margin, ~$4.2B FCF, minimal SBC, net-cash, clean taxes (23.6%). Be skeptical of the FY25 “record net income” headline (~$306M is a one-time gain, and ~$411M of float income is rate-dependent), and watch the structural RPC erosion. But the underlying operating engine is genuinely one of the best in finance.

7. Capital Allocation

Dividend policy — the CME signature. CME runs a deliberate near-100%-payout model: a steadily-rising regular quarterly dividend ($1.15/qtr in 2024 → $1.30/qtr in 2026; $5.20 annualized) plus a large annual variable (“special”) dividend sized to sweep out the year’s surplus cash. The variable dividend explicitly flexes with operating results, capex, and M&A — an honest mechanism that scales down in lean years rather than over-committing. Per-share variable dividends: FY23 $5.25 (~$1.9B), FY24 $5.80 (~$2.1B), FY25 $6.15 (~$2.2B, declared Feb 2026). Total dividends paid: $3,235.5M (FY23) → $3,584.2M (FY24) → $3,933.0M (FY25) — a clean ~10%/year climb. Against FY25 FCF of ~$4,194M, dividends alone are ~94% of FCF; with the $266.1M buyback, total cash returned (~$4,199M) is ~100% of FCF. (FACT: 10-K cash-flow statement; CEO letter.)

This is a coherent, disciplined, low-agency-cost philosophy for a capital-light, high-ROIC cash machine with essentially no organic reinvestment outlet — cash leaves the building rather than funding empire-building. The one critique: near-100% payout leaves no retained dry powder, so any large cash-funded M&A or clearing-capital demand must be debt-financed or funded by trimming the variable. Given the net-cash balance sheet, that is manageable, not acute. (INTERPRETATION.)

Buybacks — resumed as a one-off, not a pivot. CME authorized a $3.0B repurchase program (announced Dec 5, 2024); only $266.1M was deployed in FY25 (the first buybacks in years), with $2.7B remaining, and management was explicit that it is funded by the OSTTRA sale proceeds (“board has approved the use of these proceeds towards share repurchases over time”). CME historically eschewed buybacks because (1) the variable dividend already sweeps surplus cash and (2) the stock typically trades at a premium multiple, making repurchases value-dilutive vs. dividends. At a normalized P/E in the low-20s, repurchasing stock is not obviously accretive — a larger variable dividend would arguably serve shareholders better on a tax-agnostic basis. The buyback is neither a strong bullish signal (it’s windfall-funded, not conviction the stock is cheap) nor a red flag. Watch whether it persists after the OSTTRA cash is exhausted. (FACT/INTERPRETATION: 8-K; 10-K; Q4-2025 call.)

M&A — overpaid at the 2007–08 peak, disciplined since. The franchise was built by CBOT (2007, ~$11–12B), NYMEX/COMEX (2008, ~$8–9B) — both bought at the cyclical/valuation peak and followed by writedowns — and NEX (2018, ~$5.5B), the cleaner success that brought BrokerTec (cash Treasuries) and EBS (FX spot), a genuine cash-to-futures vertical synergy. The recent posture is markedly more disciplined and capital-light: OSTTRA was monetized at a gain (Oct 2025) rather than scaled with more capital; the FanDuel prediction-markets JV (Dec 2025, 51% but equity-method, only $10.2M cash contributed) and CME Securities Clearing (organic) commit almost no capital while buying optionality. The 2021 Google Cloud 10-year partnership came with a ~$1B Google equity investment in CME. Management has learned — the 2018–2025 vintage is disciplined; the 2007–08 megadeals are the (now sunk) blemish. (FACT/INTERPRETATION: 10-K Note 7; Q4-2025 call.)

Incentive alignment — above-average, not perfect. The annual cash bonus funds on “cash earnings” (114.3% of target in 2025; pays zero below threshold). Long-term incentives use relative TSR vs. the S&P 500 over three years, now enhanced with (1) an absolute 3-year net-income-margin metric and (2) a cap that limits the relative-TSR payout to 100% of target if absolute 3-year TSR is negative (you can’t win on relative TSR while shareholders lose money — a genuinely good feature), plus double-trigger change-of-control vesting. CEO Terrence Duffy’s FY25 total comp was $23.4M (flat for three years). Perks are modest (parking, personal security; no excise-tax gross-ups, no option repricing, no corporate-jet perk in the 2025 disclosure). The gaps: no explicit ROIC or per-share/EPS metric, and a dual-class governance overhang (Class B members retain trading-rights/director-election privileges) the comp committee is managing around. (FACT: 2026 proxy.)

Verdict — capital allocation STRENGTHENS the thesis. A transparent ~100%-of-FCF return via a flex-down variable dividend + rising regular dividend; a windfall monetized rather than over-invested; near-zero-capital optionality plays; trivial capex; incentives tied to profitability rather than volume/size; above-average governance hygiene. The bridge from business value to shareholder value is intact and well-managed.

8. Changes and Headwinds — Last Two Years

Strategic and corporate developments (24-month timeline). (FACT: 8-K corpus; transcripts; 10-K.)

• Dec 5, 2024: $3.0B share-repurchase authorization announced — a notable shift for a historically buyback-averse firm.
• Mar 2025: $750M 4.40% senior notes due 2030 issued to refinance the maturing $750M 3.00% 2025 notes; LT debt to $3,422.3M.
• 2025 product launches: event contracts (sports/economic/financial, Q4’25, >68M in six weeks); crypto expansion (Solana, XRP, then Cardano/Chainlink/Stellar) and a planned move to 24/7 crypto trading; one-ounce gold and 100-oz silver; FX Spot+ and BrokerTec Chicago (cash-futures side-by-side).
• Index-license extensions: Nasdaq-100 through 2039 (announced 2025) and FTSE Russell through 2037 — locking in the equity-index franchise.
• Oct 2025: OSTTRA sold to KKR ($306.1M gain; ~$1.3B net proceeds earmarked for buybacks).
• Dec 2025: FanDuel prediction-markets JV (51%, registered FCM); CME Securities Clearing receives SEC approval for the U.S. Treasury clearing mandate.
• Leadership: Lynne Fitzpatrick promoted to President & CFO; CAO/MD Jack Tobin announced retirement (Sept 2025, voluntary); other internal moves.
• Cross-margining: FICC/DTCC offsets grew to ~$1.5B/day (from ~$1B); DTCC end-user cross-margin extension announced.

Headwinds. (1) The June-2026 competitive scare — Coinbase/Kalshi CFTC-approved crypto perpetuals and the FMX/BGC attack on the SOFR/Treasury franchise, which triggered the ~17% de-rate from ~$304 to ~$252. (2) RPC erosion to $0.652 in Q1’26 (−5% YoY) on retail/micro mix. (3) Rate-cycle normalization risk after five record years. (4) Float-income compression if the Fed cuts. (5) Cloud-migration transitional duplicate costs. (6) Dual-class governance scrutiny.

Verdict — net neutral-to-slightly-strengthening on fundamentals, weakened on sentiment. The strategic moves (Treasury clearing, retail/event/crypto vectors, index-license extensions, OSTTRA monetization) genuinely strengthen the franchise and diversify growth; the headwinds are mostly sentiment and cyclical rather than evidence of a broken business. The most important structural change to monitor is the first credibly-capitalized challenger (FMX) to the rates core — still negligible in open interest, but the right attack on the right vulnerability.

9. Risk Analysis

Catastrophic-loss assessment. The probability of a total loss is very low — CME is a profitable, net-cash, systemically-important market utility. The genuine tail risks are (1) a clearing-member default cascade exceeding the margin + $100M corporate layer (mutualized to members, but franchise-damaging), and (2) a regulatory shift to open-access clearing that structurally erodes the moat. Both are low-probability/high-severity. The more probable adverse path is not catastrophe but de-rating + earnings normalization — a high-quality business re-priced from a growth multiple to a utility multiple as peak-cycle volumes soften.

10. Valuation Discussion — Embedded Expectations

No price target and no recommendation are expressed. Valuation is discussed solely as embedded expectations and scenarios.

Where CME trades. At ~$252–257 (~$91–93B market cap, ~$94B EV, net cash), CME trades at ~21.5x trailing P/E (~19.5x forward on ~$12.2 FY26 est.), ~19.7x EV/EBITDA, ~13.5x sales, a 2.0% regular dividend yield and ~4.3% all-in cash yield. Against its own ~10-year valuation history: P/E at the 46th percentile (mid-range), P/B at the 94th and P/S at the 81st (both rich). (FACT.)

Read the percentile split correctly. The mid-range P/E vs. rich P/B/P/S is the central tell. The stock fell ~17% from ~$304 yet the P/E sits only at its decade median because earnings grew into the de-rate (FY25 revenue +6%, adjusted EPS +9%) — the de-rate is a multiple event, not an earnings event so far. Crucially, P/B and P/S are unreliable for CME (negative tangible equity from merger goodwill; gross-up/mix contamination) — anchor on EV/EBITDA, normalized P/E, and FCF yield, consistent with standard exchange-valuation discipline. (INTERPRETATION.)

Normalize the one-timer. Stripping the ~$306M OSTTRA gain, normalized NI is ~$3.83B and normalized GAAP EPS ~$10.55–10.65 — so the normalized trailing P/E is closer to ~23.5–24x, slightly richer than the headline. FCF (~$11.6/share) is far less distorted; normalized FCF yield ~4.2%. (FACT.)

Peer comparison — is the premium justified?

CME carries the highest EV/EBITDA — a ~2.5–4.5-turn premium to ICE/CBOE — yet a lower P/E than CBOE/NDAQ, because its ~69% margins and minimal D&A/interest convert more EBITDA into net income. The premium is partly justified (deepest open-interest pools, a genuine clearing/cross-margin monopoly, top-of-group margins, near-zero capex making EBITDA a clean cash proxy) and partly a double bet (it is largest on the metric most flattered by CME’s capital-light structure, and CME carries the highest rate-cycle/volume cyclicality in the group — a ~3-turn premium prices both the monopoly and the durability of peak-cycle volumes). (INTERPRETATION.)

Embedded expectations — the core deliverable. With a risk-free ~4.3% and ERP ~5.0%, CME’s beta of 0.30 implies a CAPM cost of equity of only ~5.8%; even a more conservative ~6.5–7.0% leaves the low beta doing heavy lifting. For a near-100%-payout, capital-light business, a Gordon approximation (earnings yield ≈ COE − g) at ~19.5x forward (≈5.1% earnings yield) paired with a ~6.5–7.0% COE implies embedded perpetual growth of only ~1.5–2.0% — roughly inflation/GDP-like, not secular-grower pricing. At the low-beta ~5.8% COE the implied g compresses toward ~0.7% (the market paying for the low-risk annuity characteristic). Conclusion: at ~$252 the market is pricing CME closer to a low-volatility, GDP-plus utility-like compounder than a secular growth story — the de-rate removed the secular-grower premium. To justify today’s multiple, CME needs only low-single-digit durable EPS growth (ADV tracking issuance + retail, ~1–1.5% annual pricing, ~10% market-data growth) — not a continuation of 2025’s record rate-volatility volumes. The open question is whether even low-single-digit growth is safe if FY25–26 is a cyclical peak. (INTERPRETATION/ASSUMPTION.)

Scenario analysis (illustrative ranges — NOT targets).

The scenarios are unusually multiple-driven: because earnings are stable (low beta, near-full payout), most of the dispersion comes from (a) whether 2025–26 volumes normalize and (b) whether the monopoly premium in the multiple holds. The base case places fair value roughly around the current price — today’s price is a reasonable central estimate, not an obvious dislocation in either direction. (INTERPRETATION.)

Key swing factors: (1) cyclical-peak volume risk (the single biggest); (2) the rate-sensitive ~$411M float spread; (3) structural RPC erosion; (4) crypto/FMX competitive share. (FACT/OPEN QUESTION.)

11. Variant Perception

Consensus. The Street rates CME ~Hold-ish (~3.4/5) with a mean target around $308 (third-party color only — explicitly not a target). Consensus views CME as a wide-moat, low-beta, cash-generative monopoly that just printed its best-ever year, now trading at a discount to its recent multiple after a sentiment-driven sell-off — constructive but cautious, aware that 2025’s records are a hard comp.

Strongest bull case. The monopoly is real and widening ($80B/day margin savings, $25B/day rate offsets, FICC offsets growing to ~$1.5B/day); new secular vectors (retail/micros +59%, event contracts >68M in six weeks, 24/7 crypto +92%, the Treasury-clearing-mandate TAM) decouple growth from the rate cycle; pricing optionality (continuous fee reviews, +1–1.5% on flat activity, recurring market-data increases) is a low-effort lever atop a price-inelastic product; and the quality/low-beta profile (~69% margins, ~$4.2B FCF, ~4.3% cash yield, beta 0.30) is a defensive compounder that also benefits when markets are volatile.

Strongest bear case. Earnings are at a cyclical peak (five record years on elevated rate vol + issuance); RPC compression is structural, not noise (−5% YoY, lowest-fee products growing fastest); FMX and CFTC-blessed crypto-perps attack the two franchises the bull case leans on; the multiple is rich (highest EV/EBITDA in the group; P/B 94th/P/S 81st percentile); the beta-0.30 “bond proxy” de-rates if long rates stay high; and near-full payout means no internally-funded reinvestment runway — terminal value rests on the durability of the existing annuity, not a reinvestment moat.

The assumptions that matter most, and their falsification tests:

1. 2025–26 volumes are durable, not a rate-vol peak. Bear falsified if ADV holds flat-to-up across 2+ quarters of a demonstrably low-volatility regime; bull falsified if rates/energy ADV rolls over as volatility compresses.
2. The rates/clearing monopoly is non-contestable. Bear falsified if FMX/competitors fail to take meaningful SOFR/Treasury open interest within 12–18 months and CME’s OI share holds; bull falsified if a credible competitor captures sustained, growing OI in the benchmark rate contracts.
3. RPC stabilizes. Bull falsified if blended RPC keeps falling >3–4%/yr as retail/micro mix dominates; bear falsified if the continuous fee changes hold blended RPC roughly flat.
4. Float income is resilient to Fed cuts. Bear strengthened if a cutting cycle materially compresses the ~$411M spread.
5. The EV/EBITDA monopoly premium is justified. Bull falsified if CME’s premium to ICE/CBOE compresses as the market re-rates it toward a cyclical exchange; bear falsified if CME sustains its premium through a volume-normalization year.

Net read. The genuine debate is cyclical-peak-vs-secular-grower, refracted through one number — the highest EV/EBITDA in the peer group. The de-rate from ~$304 to ~$252 has already stripped much of the secular-grower premium, so the variant question is now: has the market over-corrected a high-quality monopoly toward utility pricing, or correctly begun re-rating a peak-cycle, increasingly-contested franchise?

12. Fact vs. Interpretation Table

13. Open Questions

1. Are FY25–26 volumes a cyclical peak? The single most important unknown. Five record years coincide with elevated rate volatility and heavy issuance; the durability of that demand in a low-volatility regime is unproven.
2. How fast does RPC erode, and does continuous pricing offset it? Q1’26 −5% is a clear signal; the trajectory determines whether revenue keeps decoupling downward from contract growth.
3. Can FMX (or any LCH-cross-margin challenger) ever assemble a credibly large alternative offset pool? Negligible today, but the only structurally-correct attack on the captivity lock.
4. What is the steady-state opex effect of the Google Cloud migration — a genuine cost reduction or merely a re-basing?
5. What is the adequacy of the $100M corporate “skin-in-the-game” layer in an extreme multi-default scenario (unquantifiable from filings)?
6. Does the buyback persist after the OSTTRA cash is exhausted — the more meaningful capital-allocation signal?
7. Historical rates-challenger failures (Eurex US, ELX, NYSE Liffe US) were cited but not independently re-verified from primary sources this session.

14. What Must Be True

Bull case — what must be true: (1) 2025–26 volumes prove structural, not a rate-vol peak — ADV grows or holds through a normal-volatility regime; (2) the open-interest/clearing monopoly remains non-contestable — FMX and crypto-perps fail to take sustained benchmark open interest; (3) the secular retail/event/crypto/clearing vectors scale enough to offset RPC mix erosion and keep revenue compounding mid-single-digits-plus; (4) the EV/EBITDA premium holds because the market continues to underwrite the monopoly/clearing economics as durable.

• Falsification test: rates/energy ADV rolls over as volatility compresses and blended RPC keeps falling >3–4%/yr — confirming peak-cycle earnings with structural pricing erosion. If both occur across 2+ quarters, the bull thesis is broken regardless of multiple.

Bear case — what must be true: (1) FY25 earnings are a cyclical high that mean-reverts as rate volatility and issuance normalize; (2) RPC compression is structural and accelerating; (3) the rich, highest-in-group multiple de-rates as a beta-0.30 bond proxy in a higher-for-longer regime and/or as a competitor (FMX) proves the rates moat contestable; (4) near-full payout caps reinvestment-driven compounding.

• Falsification test: CME sustains its EV/EBITDA premium through a demonstrably low-volatility year while holding blended RPC roughly flat — proving the volumes are structural and the moat/pricing intact. If that happens, the bear’s “peak + erosion + de-rate” case collapses.

15. Source Appendix

Primary sources: CME Group FY2025 Form 10-K (filed 2026-02-26, EDGAR cme-20251231.htm), FY2024 10-K (cme-20241231.htm), Q1 2026 10-Q (cme-20260331.htm), the 8-K corpus (2023–2026), the 2026 DEF 14A proxy, and the Q2/Q3/Q4-2025 earnings-call transcripts. Quantitative data reconciled via SEC EDGAR XBRL (CIK 0001156375), third-party market-data aggregators for peer multiples (as of June 5–8, 2026). All accessed 2026-06-08.

This memo expresses no investment recommendation and no price target (the sole exception being the clearly-labeled “Claude’s Take” block at the top, which is the author’s own subjective view and general information, not investment advice). Management commentary has been treated as hypothesis and validated against filings, financials, and external evidence throughout.

APPENDIX A — Standard Diligence Questionnaire

CME Group Inc. (NASDAQ: CME) — Standard Diligence Questionnaire Appendix

Diligence questionnaire. Fact/Interpretation/Assumption labels where they matter. Report date: 2026-06-08.

General

What thoughtful questions have other investors asked about this company? The recurring institutional questions cluster on five axes: (1) Are volumes cyclical or secular? — i.e., is the five-year ADV record streak a rate-volatility artifact that mean-reverts? (2) RPC durability — why blended rate-per-contract keeps drifting down (Q1’26 −5% YoY) and whether retail/micro mix permanently dilutes pricing. (3) The retail strategy — how additive Robinhood/event-contracts/24-7 crypto really are, and whether they cannibalize RPC. (4) Capital return — buyback intentions now that the $3B authorization exists, vs. the variable-dividend tradition. (5) Competitive threats — FMX’s Treasury-futures attack and the FCM-license question (does CME intend to disintermediate its clearing-firm partners?). On the Q4-2025 call, analysts pressed specifically on the FCM license (management: “I am not looking to dislocate or disintermediate any of my FCMs today”) and on buyback cadence. (Fact: transcripts.)

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Interpretation: Likely a cyclical high. FY25 was the fifth consecutive record-volume year, driven by elevated rate volatility, heavy Treasury issuance, and commodity dislocation (metals ADV +34%). The largest complex (interest rates, ~50% of volume) is the most rate-cycle-sensitive. A reversion to low volatility is the primary normalization risk.

Driven by the external environment or internal actions? Both, but external dominates. The external environment (rate uncertainty, issuance, geopolitical risk, commodity volatility) drives volumes; internal actions (new products, retail partnerships, pricing, cross-margining) add a secular layer that is real but still small relative to the cyclical core.

How stable are revenues? Moderately stable for a transaction business: ~81% is transaction-driven (recurs with volume), ~12% (market data) is subscription-recurring and grew 31 consecutive quarters, ~7% other. Diversification across six asset classes lowers aggregate volatility vs. a single-product exchange. (Fact: 10-K.)

Outlook for products/services? Growing — issuance/hedging demand expands structurally; new vectors (retail, events, 24/7 crypto, Treasury clearing) add optionality. But the fastest-growing products carry the lowest RPC.

How big will this market be — growing, shrinking, domestic or international? Growing and increasingly international (~30% of volume; EMEA/APAC growing double-digits). Global listed-derivatives volumes rise with debt issuance, risk-transfer needs, and Basel/Dodd-Frank clearing mandates.

Business Quality & Competitive Moat

Is the industry getting more or less competitive? Interpretation: The core is stable; the perimeter is more contested than in a decade (FMX in rates, Coinbase/Kalshi in crypto-perps, prediction markets in events). The benchmark open-interest pools remain near-monopolies.

How profitable is the business (ROIC, ROE)? Exceptionally so. GAAP operating margin 64.9% (adjusted 69.4%); ROE ~14.8% understates true returns because ~$30B of merger goodwill inflates the denominator. On tangible operating capital (property just $362.7M) the business is nearly capital-free and earns several-hundred-percent returns. Use ROIC/FCF, not ROE/P/B (negative tangible equity). (Fact/Interpretation.)

How profitable is the industry — how many competitors, what barriers to entry? A handful of integrated operators, each dominant in its silo. Barriers are very high: regulatory (DCM + DCO registration), the liquidity/open-interest network effect, and the owned-clearinghouse fungibility lock. ~100% incremental margins.

Can the business be easily understood? Yes at a high level (toll on every futures trade + clearing fee + margin float + data subscriptions), though the clearing/margin mechanics and the custodial balance-sheet gross-up require care.

Can it be undermined by foreign low-cost labor? No — it is a regulated, network-effect electronic utility, not labor-arbitrageable.

Do brands matter? Yes, in the form of benchmark status — “the CME price” is the reference (WTI, Henry Hub, SOFR, E-mini S&P, COMEX gold). Benchmark ownership is a durable intangible.

What is the nature of competition? Liquidity competition (deepest book wins) and capital-efficiency competition (cross-margin offsets). Price competition is muted in the silo’d core but real at the fungible/contestable edges.

Customers’ switching costs? Very high and quantified: ~$80B/day of cross-asset margin savings is forfeited by leaving CME; open interest cannot migrate without coordinated close-and-reopen. This is the single best evidence of the moat.

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? Yes — the franchise value: indefinite-lived trading-product intangibles ($17.2B) and the irreproducible exchange/clearing license are carried at historical cost, not economic value; the ~27% S&P/DJI stake ($1.4B carrying) is worth more than book.

Off-balance-sheet liabilities? The clearing default waterfall / guaranty fund — CME’s corporate “skin in the game” is only $100M before non-defaulting members are assessed, against $347.3B of member collateral. A tail contingency. (Fact: 10-K financial-safeguards note.)

How conservative is the accounting? Conservative. OCF > NI every year; minimal SBC ($94.8M); the one-time OSTTRA gain is clearly disclosed; taxes clean (23.6%). The main “watch” is that ~$411M of rate-sensitive float income and the equity-method line sit in non-operating income.

How CapEx-hungry is the business? Barely — capex $83.5M (~1.3% of revenue), guided ~$85–90M. Asset-light to the extreme.

Capital Allocation & Management

How much FCF, how is it used, what is the philosophy? ~$4.2B FCF (FY25), ~100% returned: a rising regular dividend ($5.20/yr) + a large annual variable special dividend ($6.15/sh, ~$2.2B) that flexes with cash earnings, plus a one-time OSTTRA-funded buyback. Philosophy: return nearly all cash since there is no organic reinvestment outlet. (Fact: cash-flow statement.)

Significant acquisitions recently? No cash-heavy deals recently — the opposite: OSTTRA sold to KKR (Oct 2025, $306M gain); FanDuel JV (Dec 2025, only $10.2M); CME Securities Clearing built organically. Disciplined, capital-light. (Legacy CBOT/NYMEX 2007–08 were overpaid at the peak.)

Buying back shares? Newly, yes — $266.1M in FY25 (first in years), $3.0B authorized Dec 2024, funded by OSTTRA proceeds. A one-off windfall deployment, not obviously accretive at a premium multiple. (Interpretation.)

Issuing large amounts of new shares to insiders? No — SBC is just ~1.5% of revenue and share count fell.

Compensation policy of directors/management? CEO Duffy ~$23.4M (flat 3 yrs); bonus on “cash earnings”; LTI on relative TSR vs. S&P 500 + a new net-income-margin metric + a negative-absolute-TSR payout cap; modest perks, no gross-ups, no jet. Above-average hygiene; gaps are no explicit ROIC/EPS gate and a dual-class structure. (Fact: 2026 proxy.)

Motivations of management? Aligned with profitability and shareholder-relative returns rather than raw volume/size; long-tenured, founder-like CEO. Reasonable alignment.

Valuation & Market Data

Is the stock an ADR, MLP, or K-1 issuer? No — ordinary U.S. C-corp common stock (Class A), NASDAQ-listed. (A small Class B membership share class carries trading-rights/director-election privileges — a governance feature, not a tax structure.)

Dividend policy? Regular quarterly ($1.30) + annual variable special ($6.15 FY25); ~4.3% all-in cash yield; near-100% of FCF.

How profitable is the business? ~62.5% net margin; ~64% FCF margin — among the most profitable business models in any industry.

Is net income diverging from cash from operations? No — OCF exceeds NI every year (1.05x in FY25). High earnings quality. (Note the headline “net change in cash” is meaningless due to custodial collateral flows in financing.)

Risks & Downside

What factors would cause the stock to decline? Rate-cycle volume normalization; accelerating RPC erosion; Fed cuts compressing the ~$411M float spread; a credible rates competitor (FMX) taking open interest; multiple de-rating (bond-proxy) in a higher-for-longer regime; a clearing-default event.

Risk of a catastrophic loss? Low — net-cash, systemically-important, profitable utility. The genuine tails are a clearing-default cascade beyond the margin + $100M layer, or a regulatory shift to open-access clearing.

Chance of a total loss? Very low. The more realistic adverse path is de-rating + earnings normalization, not impairment of the franchise.

Recent News & Events

Has the business environment changed recently? Yes, on two fronts: (1) competitive — June 2026 CFTC approval of Coinbase/Kalshi crypto perpetuals and the ongoing FMX (Lutnick/BGC) attack on the Treasury/SOFR franchise triggered a ~17% de-rate; (2) regulatory tailwind — SEC approval of CME Securities Clearing for the mandatory U.S. Treasury clearing regime (effective 12/31/2026). (Fact: company disclosures; CFTC.)

Significant acquisitions? OSTTRA sold (Oct 2025); FanDuel prediction-markets JV (Dec 2025).

Change in accounting policies? None material identified.

Recent changes — new markets, facilities, management? Lynne Fitzpatrick promoted to President & CFO; CAO Jack Tobin retiring; new products (event contracts, 24/7 crypto, 100-oz silver, BrokerTec Chicago); Nasdaq-100 (2039) and FTSE Russell (2037) license extensions; $750M 2030 notes issued.

APPENDIX B — Source Appendix

CME Group Inc. (NASDAQ: CME) — Source Appendix

Report date: 2026-06-08. Primary sources prioritized. All accessed 2026-06-08 unless noted.

Primary — SEC Filings (EDGAR, CIK 0001156375)

All filings are publicly available on SEC EDGAR (CIK 0001156375).

Primary — Earnings-Call Transcripts

Quantitative Data Helpers

Secondary — Industry / Competitive

Frameworks Applied

• Greenwald & Kahn, “Competition Demystified” — moat taxonomy (economies of scale + customer captivity), market-share-stability and ROIC tests.
• Chancellor / Marathon, “Capital Returns” — supply-side capital-cycle analysis (capital floods the perimeter, not the protected core).

Management commentary treated as hypothesis and validated against filings, financials, and external evidence throughout. No price target or BUY/SELL recommendation appears in the memo body — the sole exception is the clearly-labeled “Claude’s Take” block.